- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00691288
Effect of Omega-3 Fatty Acid Supplementation on Hypertriglyceridemia in HIV-infected Children
Effect of Omega-3 Fatty Acid Supplementation on Hypertriglyceridemia in HIV-infected Children Taking Highly Active Antiretroviral Therapy (HAART): a Randomized Cross-over Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
There are no guidelines as to the clinical threshold at which treatment for hypertriglyceridemia is necessary in pediatric populations, and extreme hypertriglyceridemia is relatively infrequent in HIV-infected children. Adult studies have suggested that there is a proportionate reduction in triglycerides of approximately 15-25% when taking fish oil omega-3 fatty acid supplementation, irrespective of the degree of initial triglyceride elevation. This trial would thus represent a proof-of-concept study in children with mild to moderate hypertriglyceridemia.
The results of this study would contribute to the pool of knowledge regarding the efficacy and safety of this nutriceutical in the treatment of HAART-associated hypertriglyceridemia in children. Compared with other interventions (such as dietary changes and drug therapies), nutritional supplementation with fish oil is an inexpensive, simple, and likely preferable treatment for a potentially significant medical condition. In addition, the results of this study could presumably be extrapolated to benefit children with hypertriglyceridemia secondary to other types of drugs or illnesses.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada
- The Hospital for Sick Children
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- HIV positive children aged 5-18 years on stable HAART therapy for at least 6 months, with reasonable control of their HIV (viral load remaining undetectable, or stable with <0.5 log increase in previous 3-4 months) and no plans for a change in therapy in the next year
- Elevated fasting triglyceride level >1.5 mmol/L on at least two occasions within the previous year (including at least one in the last 3 months while on the current HAART regimen)
- Ability to swallow capsules
Exclusion Criteria:
- Known allergy to fish, soybean, or corn
- Current treatment with triglyceride-lowering agent
- Family history of familial hypertriglyceridemia
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: 1
|
Subjects in this arm will begin the study on active capsules (containing Omega Pure).
Subjects in the 5-11 age group will take 2 capsules containing 500mg EPA/DHA twice daily for 12 weeks.
Subjects in the 12-18 age group will take 2 capsules containing 1.0g EPA/DHA twice daily, also for a period of 12 weeks.
Both age groups will then be switched to the placebo capsules containing citrus-flavoured soybean and corn oil, identical in appearance to the active agent, to be taken on an identical regimen to the active pills, for a period of 12 weeks.
Other Names:
|
EXPERIMENTAL: 2
|
Patients assigned to this arm of the study will begin on placebo followed by Omega Pure (identical dose and regimen as arm 1), also for a period of 12 weeks each.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Percentage change in triglyceride levels
Time Frame: 4 and 12 weeks after beginning treatment
|
4 and 12 weeks after beginning treatment
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Changes in cholesterol profiles (LDL, HDL, and total:HDL ratio), amylase, platelet function, AST, and ALT
Time Frame: 4 and 12 weeks after beginning treatment
|
4 and 12 weeks after beginning treatment
|
Reporting of side effects, compliance, and discontinuation
Time Frame: 4 and 12 weeks after beginning treatment
|
4 and 12 weeks after beginning treatment
|
Effect on control of HIV (vial load, CD4)
Time Frame: 12 weeks after beginning treatment
|
12 weeks after beginning treatment
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Ari Bitnun, MD, MSc, The Hospital for Sick Children
- Principal Investigator: Jason Brophy, MD, The Hospital for Sick Children
- Principal Investigator: Stanley Read, MD, PhD, The Hospital for Sick Children
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1000011295
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertriglyceridemia
-
Arrowhead PharmaceuticalsNot yet recruitingSevere Hypertriglyceridemia
-
89bio, Inc.RecruitingSevere HypertriglyceridemiaUnited States, Bulgaria, Canada, Latvia, Spain, Austria, Belgium, Czechia, Georgia, Hungary, Poland, Puerto Rico, Argentina, Chile, France, Germany, United Kingdom
-
Ionis Pharmaceuticals, Inc.RecruitingSevere HypertriglyceridemiaUnited States, Germany, Israel, Spain, Netherlands, Australia, Hungary, Sweden, Denmark, Canada, France, Italy, Turkey, Finland, Bulgaria, Czechia, New Zealand, Norway, Poland, Portugal, Slovakia, South Africa, United Kingdom
-
Sancilio and Company, Inc.WithdrawnSevere Hypertriglyceridemia
-
Arrowhead PharmaceuticalsCompletedSevere HypertriglyceridemiaUnited States, Netherlands, Australia, Canada, New Zealand, Poland, Hungary, Germany
-
AstraZenecaCompletedSevere HypertriglyceridemiaUnited States, Hungary, India, Russian Federation, Denmark, Ukraine, Netherlands
-
AstraZenecaRadiant ResearchCompletedSevere HypertriglyceridemiaUnited States
-
Trygg Pharma, Inc.UnknownSevere HypertriglyceridemiaUnited States
-
National Taiwan University HospitalUnknownHypertriglyceridemia During PregnancyTaiwan
-
DongKoo Bio & PharmaUnknownHyperlipidemia, HypertriglyceridemiaKorea, Republic of
Clinical Trials on Omega Pure followed by placebo
-
Hoffmann-La RocheCompleted
-
Portuguese Oncology Institute, CoimbraCompletedColorectal Cancer | Recurrence, Local NeoplasmPortugal
-
Hospices Civils de LyonUnknownSevere Refractory Neuropathic Pain | Spinal Cord Lesions
-
American University of Beirut Medical CenterUnknownAnesthesia, RecoveryLebanon
-
Kraft Heinz CompanyBioFortisCompleted
-
Centre for Addiction and Mental HealthUniversity Health Network, TorontoCompletedMajor DepressionCanada
-
Hanmi Pharmaceutical Company LimitedCompletedDiabetes MellitusKorea, Republic of
-
BiondVax Pharmaceuticals ltd.Completed
-
Hartford HospitalRecruiting
-
Norwegian University of Science and TechnologySykehuset Innlandet HF; Norwegian Foundation for Health and Rehabilitation; Norwegian... and other collaboratorsCompletedIrritable Bowel Syndrome | Functional Gastrointestinal DisordersNorway